Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-07-07
DOI
10.1111/bjh.18295
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma
- (2022) Peter O'Gorman et al. AMERICAN JOURNAL OF HEMATOLOGY
- Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group
- (2021) Evangelos Terpos et al. LANCET ONCOLOGY
- A clinical perspective on plasma cell leukemia; current status and future directions
- (2021) Sherilyn A. Tuazon et al. Blood Cancer Journal
- Upfront Carfilzomib, Lenalidomide, Dexamethasone with Transplant in Multiple Myeloma Patients, the IFM KRd final results
- (2021) Murielle Roussel et al. BLOOD
- Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
- (2021) Ola Landgren et al. JAMA Oncology
- Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial
- (2021) Hartmut Goldschmidt et al. BLOOD
- Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
- (2021) Thierry Facon et al. LANCET ONCOLOGY
- Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd
- (2020) Maria-Victoria Mateos et al. BLOOD
- Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
- (2020) Luciano J. Costa et al. BLOOD
- Combination lenalidomide/bortezomib treatment synergistically induces calpain-dependent Ikaros cleavage and apoptosis in myeloma cells
- (2020) Saravanan Ganesan et al. MOLECULAR CANCER RESEARCH
- Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN
- (2020) Peter M Voorhees et al. BLOOD
- Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma
- (2020) Nisha S. Joseph et al. JOURNAL OF CLINICAL ONCOLOGY
- Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
- (2020) Jagoda Jasielec et al. BLOOD
- Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard and high risk myeloma
- (2020) Ibai Goicoechea et al. BLOOD
- The role of high‐dose melphalan with autologous stem‐cell transplant in multiple myeloma: is it time for a paradigm shift?
- (2020) Dickran Kazandjian et al. BRITISH JOURNAL OF HAEMATOLOGY
- Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
- (2020) Meletios Dimopoulos et al. LANCET
- Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
- (2020) Michele Cavo et al. Lancet Haematology
- Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
- (2020) Shaji K Kumar et al. LANCET ONCOLOGY
- Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone ( VRd ) as first‐line therapy in multiple myeloma
- (2020) Joselle Cook et al. AMERICAN JOURNAL OF HEMATOLOGY
- Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma
- (2019) Edward A. Stadtmauer et al. JOURNAL OF CLINICAL ONCOLOGY
- Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
- (2019) Alok A. Khorana et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- (2019) Philippe Moreau et al. LANCET
- Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
- (2019) Paul G Richardson et al. LANCET ONCOLOGY
- Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center
- (2019) Patrick Yau et al. LEUKEMIA & LYMPHOMA
- Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplantation in multiple myeloma
- (2019) Laura Rosiñol et al. BLOOD
- RVD with weekly subcutaneous bortezomib minimizes neuropathy and maintains efficacy in a diverse multiple myeloma cohort
- (2019) Amitoj Gill et al. Clinical Lymphoma Myeloma & Leukemia
- Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR
- (2019) Maria-Victoria Mateos et al. Clinical Lymphoma Myeloma & Leukemia
- The efficacy and safety of modified bortezomib‐lenalidomide‐dexamethasone in transplant‐eligible patients with newly diagnosed multiple myeloma
- (2019) Kiyoshi Okazuka et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis
- (2019) Karthik Ramasamy et al. LEUKEMIA & LYMPHOMA
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- (2019) Michel Attal et al. LANCET
- Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
- (2019) Maria-Victoria Mateos et al. LANCET
- Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
- (2019) Mark T Drayson et al. LANCET ONCOLOGY
- A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma
- (2018) Elizabeth K. O'Donnell et al. BRITISH JOURNAL OF HAEMATOLOGY
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
- (2018) Marc Carrier et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
- (2018) Paul G. Richardson et al. Blood Cancer Journal
- Bisphosphonate guidelines for treatment and prevention of myeloma bone disease
- (2017) Oi Lin Lee et al. INTERNAL MEDICINE JOURNAL
- Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
- (2017) Philip L. McCarthy et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
- (2017) Brian G M Durie et al. LANCET
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
- (2017) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Complications of Multiple Myeloma Therapy, Part 1: Risk Reduction and Management of Peripheral Neuropathy and Asthenia
- (2017) Paul G. Richardson et al. Journal of the National Comprehensive Cancer Network
- N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma
- (2016) Paolo Milani et al. AMERICAN JOURNAL OF HEMATOLOGY
- Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
- (2016) Rachid C. Baz et al. BLOOD
- VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
- (2016) Philippe Moreau et al. BLOOD
- Trends in overall survival and costs of multiple myeloma, 2000–2014
- (2016) R Fonseca et al. LEUKEMIA
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
- (2015) A. Palumbo et al. BLOOD
- Practical Management of Lenalidomide-Related Rash
- (2015) Sara M. Tinsley et al. Clinical Lymphoma Myeloma & Leukemia
- Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data
- (2015) Michael H. Andreae et al. JOURNAL OF PAIN
- Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
- (2015) Neha Korde et al. JAMA Oncology
- Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment
- (2014) C. Pawlyn et al. BLOOD
- A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
- (2014) P. G. Richardson et al. BLOOD
- Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma
- (2014) Min Jung Lee et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy
- (2014) M.-V. Mateos et al. HAEMATOLOGICA
- Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome
- (2014) Murielle Roussel et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy-induced peripheral neuropathies in hematological malignancies
- (2014) Joost Louis Marie Jongen et al. JOURNAL OF NEURO-ONCOLOGY
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
- (2014) Lotfi Benboubker et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Positive Effects of One-Hour Intravenous Administration of Bortezomib on Peripheral Neuropathy in Multiple Myeloma Patients
- (2014) Joo Young Jung et al. Biomed Research International
- International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease
- (2013) Evangelos Terpos et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
- (2012) S. Kumar et al. BLOOD
- Desensitization to Lenalidomide in a Patient With Relapsed Multiple Myeloma
- (2012) Jack T. Seki et al. Clinical Lymphoma Myeloma & Leukemia
- Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study
- (2012) D H Vesole et al. LEUKEMIA
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
- (2011) Philippe Moreau et al. LANCET ONCOLOGY
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
- (2010) P. G. Richardson et al. BLOOD
- Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus
- (2010) Mitchell S. Cairo et al. BRITISH JOURNAL OF HAEMATOLOGY
- Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations
- (2010) B. Mohty et al. HAEMATOLOGICA
- Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
- (2009) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
- (2009) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
- (2009) C B Reeder et al. LEUKEMIA
- Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study
- (2008) Asher Chanan-Khan et al. JOURNAL OF CLINICAL ONCOLOGY
- Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
- (2008) Bertrand Coiffier et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now